EURÓPSKA KOMISIA SCHVÁLILA LIEK IMDYLLTRA® SPOLOČNOSTI AMGEN NA LIEČBU POKROČILÉHO ŠTÁDIA MALOBUNKOVÉHO KARCINÓMU PĽÚC
RegulatoryapprovedIMDYLLTRAPositive
AI Analysis
Summary
The European Commission approved Amgen's IMDYLLTRA for advanced stage small cell lung cancer based on Phase 3 DeLLphi-304 data demonstrating a 40% reduction in mortality risk compared to chemotherapy.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
European Commission approval for advanced stage small cell lung cancer based on Phase 3 DeLLphi-304 trial showing 40% reduction in mortality risk versus chemotherapy
Importance:9/10
Sentiment:
0.90
regulatory approvalEuropeoncologysmall cell lung cancerPhase 3
Related Companies
Read the original article
Published by PR Newswire Pharma on June 3, 2026 6:25 PM